Telix Pharmaceuticals Limited announced a webinar scheduled for March 4-5, 2026, featuring key opinion leaders discussing innovations in PSMA-PET/CT imaging for prostate cancer. The event will include speakers from the University of Melbourne, UroPartners, and Telix leadership, moderated by the company's Chief Medical Officer.

Telix Pharmaceuticals, an Australian nuclear medicine company, is gaining attention for its cancer-targeting radiopharmaceuticals used for both detection and treatment. With 56% revenue growth in 2025, recent regulatory approvals for lead products Illuccix and Gozellix, and ownership of a 31-location radiopharmacy distribution network, analysts project the stock could triple from current levels. The company has multiple pipeline candidates in late-stage trials and a market cap of $2.3 billion.

Levi & Korsinsky announces a class action securities lawsuit against Telix Pharmaceuticals Ltd. for alleged securities fraud between February 21, 2025 and August 28, 2025. The complaint alleges the company made false statements about prostate cancer therapeutic progress, overstated supply chain quality, and made misleading statements about business operations. The lead plaintiff deadline is January 9, 2026.

Telix Pharmaceuticals announced that Managing Director and Group CEO Dr. Christian Behrenbruch will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will provide an overview of the company's pipeline assets and commercial portfolio, with a webcast available live and on-demand. Fourth quarter 2025 financials will be released on January 20, 2026.

Levi & Korsinsky has filed a class action securities lawsuit against Telix Pharmaceuticals Ltd. on behalf of investors who suffered losses between February 21, 2025 and August 28, 2025. The complaint alleges that defendants made false statements regarding prostate cancer therapeutic progress, overstated supply chain quality, and made materially misleading statements about the company's business and prospects. The deadline to request lead plaintiff status is January 9, 2026.

Bragar Eagel & Squire, P.C. has announced class action lawsuits against Agilon Health, Charming Medical, and Telix Pharmaceuticals for allegedly making false or misleading statements to investors. Agilon is accused of issuing unachievable 2025 guidance and overstating financial impacts from strategic actions. Telix is accused of overstating prostate cancer drug progress and supply-chain quality. Investors who purchased securities during specified periods are encouraged to contact the firm.

Multiple class action lawsuits have been filed against healthcare and pharmaceutical companies. Charming Medical faced a fraudulent stock promotion scheme involving social media misinformation that artificially inflated its stock price before SEC trading halt. Agilon Health and Telix Pharmaceuticals also face investor lawsuits, with Telix accused of overstating drug progress and supply-chain quality.

A class action lawsuit has been filed against Telix Pharmaceuticals Limited in the U.S. District Court for the Southern District of Indiana. The lawsuit alleges that defendants made false and misleading statements regarding prostate cancer therapeutic candidates, overstated supply chain quality, and misrepresented business operations and prospects during the period of February 21, 2025 to August 28, 2025. Investors have until January 9, 2026 to apply to be appointed as lead plaintiff.

Law Offices of Howard G. Smith announces securities fraud class action lawsuits against four publicly-traded companies. Six Flags Entertainment faces allegations of underinvestment in parks and misleading merger disclosures. Telix Pharmaceuticals is accused of overstating therapeutic progress and supply chain quality. Stride, Inc. is alleged to have inflated enrollment numbers and ignored compliance requirements. Primo Brands is charged with failing to disclose poor merger integration and supply disruptions. Lead plaintiff deadlines range from January 5-12, 2026.

Hagens Berman has filed a securities class action lawsuit against Telix Pharmaceuticals (NASDAQ: TLX) alleging the company materially overstated developmental progress and misrepresented supply chain reliability. The lawsuit follows an SEC subpoena regarding drug development disclosures and an FDA Complete Response Letter rejecting the Zircaix application due to Chemistry, Manufacturing, and Controls deficiencies. These regulatory setbacks triggered a 21% stock decline. The lead plaintiff deadline is January 9, 2026.

Hagens Berman has filed securities class action lawsuits against Stride Inc. (LRN), Telix Pharmaceuticals (TLX), and Klarna Group (KLAR) alleging various fraudulent practices and regulatory failures. Stride faces allegations of inflating enrollment figures with 'Ghost Students' and concealing a critical technology platform failure that caused a 54% stock crash. Telix is accused of regulatory failures including an SEC subpoena and FDA Complete Response Letter. Klarna is being sued over a 102% spike in credit loss provisions and inadequate risk disclosures. Lead plaintiff deadlines range from January 9-12, 2026.

Rosen Law Firm has filed securities class action lawsuits against Freeport-McMoRan Inc., Telix Pharmaceuticals Ltd., and National Grid plc. The FCX lawsuit alleges the company made false statements regarding safety at its Grasberg Block Cave mine in Indonesia and failed to disclose heightened regulatory and reputational risks. Investors who purchased securities during specified class periods are encouraged to join the litigation before upcoming deadlines.